Print Article | Back to Articles

Denosumab Dose Selection for Patients with Bone Metastases from Solid Tumors Clinical Cancer Research, 05/02/2012

Doshi S et al. – Over the wide range of dosing regimens examined, a s.c. denosumab dose of 120mg administered every 4 weeks is the optimal dosing regimen to suppress urinary N–telopeptide normalized to urinary creatinine (uNTx/Cr) in patients with bone metastases from solid tumors.

Read this article on Clinical Cancer Research

Print Article | Back to Articles

Stay current on the latest literature, research and clinical news
Get special communications and offers from MDLinx and our sponsors
Receive invitations to paid market research

View Samples and Register

Stay current - Media Tool

Newsletter

RSS

Facebook

Receive free subspecialty
"5-minute updates" via email

Send the E-mail Newsletter to a Colleague

♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦

♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦

♦ Follow Us on Facebook

Search the latest
Internal Medicine Jobs
@MDLinx Career Center
View the full listing of physician jobs

Enter your email address and your password will be sent to you.
Email:

E-mail:
Password:
	Remember me Forgot your password?